Rocket Pharmaceuticals Highlights Genetic Therapy Innovations at J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals Showcases Commitment to Genetic Therapies at J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals, Inc., a late-stage biotechnology firm specializing in genetic therapies for rare disorders, announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Scheduled for January 13, Dr. Gaurav Shah, the CEO, will present the company’s strategic vision at 3:45 p.m. PT, followed by a series of investor meetings throughout the event. This appearance not only underscores Rocket’s ongoing commitment to advancing genetic therapies but also positions the company to engage with key stakeholders in the healthcare sector.

At the conference, Rocket Pharmaceuticals highlights its innovative pipeline of investigational therapies designed to target the root causes of complex rare diseases. The company’s lentiviral vector-based portfolio includes advanced programs for conditions such as Fanconi Anemia (FA), a critical condition leading to bone marrow failure, and Leukocyte Adhesion Deficiency-I (LAD-I), a severe genetic disorder that results in life-threatening infections. Additionally, Rocket is actively developing treatments for Pyruvate Kinase Deficiency (PKD), a disorder that causes anemia. These initiatives reflect Rocket's strategic focus on rare diseases, which often lack effective treatment options.

Rocket's commitment to transforming patient care extends into the cardiovascular domain with its adeno-associated viral vector-based portfolio. This includes a late-stage program targeting Danon Disease, a condition linked to heart failure, and ongoing clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM). The company is also advancing a pre-clinical program aimed at BAG3-associated dilated cardiomyopathy (DCM). By investing in these transformative therapies, Rocket Pharmaceuticals seeks not only to address significant unmet medical needs but also to enhance the overall quality of life for patients grappling with debilitating conditions.

In conjunction with its conference participation, Rocket Pharmaceuticals encourages interested parties to access a live webcast of the presentation via its website. The company underscores its proactive engagement with the investor community on social media platforms as well. Additionally, Rocket includes a cautionary statement regarding forward-looking statements, acknowledging the inherent risks and uncertainties in the biotechnology sector that may affect its future outcomes and expectations.